Current role of ultrasound in chronic liver disease: Surveillance, diagnosis and management of hepatic neoplasms

Current Problems in Diagnostic Radiology

Volumn 41, Issue 2, 2012, Pages 43-51

  Irshad, Abid ^a   Anis, Munazza ^a   Ackerman, Susan J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER SURGERY; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE SURVEILLANCE; DOPPLER ECHOGRAPHY; ECHOGRAPHY; HUMAN; IMAGE QUALITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOFREQUENCY ABLATION; REVIEW;

CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MASS SCREENING; SENSITIVITY AND SPECIFICITY; SENTINEL SURVEILLANCE;

EID: 84856347616     PISSN: 03630188     EISSN: 15356302     Source Type: Journal    
DOI: 10.1067/j.cpradiol.2011.07.003     Document Type: Review

References (49)

1. Harvey C.J., Albrecht T. Ultrasound of focal liver lesions. Eur Radiol 2001, 11:1578-1593.
2. Shapiro R.S., Wagreich J., Parsons R.B., et al. Tissue harmonic imaging sonography: Evaluation of image quality compared with conventional sonography. AJR 1998, 171:1203-1206.
3. Hann L.E., Bach A.M., Cramer L.D., et al. Hepatic sonography: Comparison of tissue harmonic and standard sonography techniques. AJR 1999, 173:201-206.
4. Whittingham T.A. Tissue harmonic imaging. Eur Radiol 1999, 9(suppl 3):S323-S326.
5. Taylor K.J., Ramos I., Morse S.S., et al. Focal liver masses: Differential diagnosis with pulsed Doppler US. Radiology 1987, 164:643-647.
6. Nino-Murcia M., Ralls P.W., Jeffrey R.B., et al. Color flow Doppler characterization of focal hepatic lesions. AJR 1992, 159:1195-1197.
7. Choi B.I., Kim T.K., Han J.K., et al. Power versus conventional color Doppler sonography: Comparison in the depiction of vasculature in liver tumors. Radiology 1996, 200:55-58.
8. Lencioni R., Pinto F., Armillotta N., et al. Assessment of tumor vascularity in hepatocellular carcinoma: Comparison of power Doppler US and color Doppler US. Radiology 1996, 201:353-358.
9. Gaiani S., Volpe L., Piscaglia F., et al. Vascularity of liver tumours and recent advances in Doppler ultrasound. J Hepatol 2001, 34:474-482.
10. Izzo F., Cremona F., Delrio P., et al. Soluble interleukin-2 receptor levels in hepatocellular cancer: A more sensitive marker than alfa fetoprotein. Ann Surg Oncol 1999, 6:178-185.
11. Tong M.J., Blatt L.M., Kao V.W. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001, 16:553-559.
12. Larcos G., Sorokopud H., Berry G., et al. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: An evaluation. AJR 1998, 171:433-435.
13. Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22:432-438.
14. Chalasani N., Horlander J.C., Said A., et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1999, 94:2988-2993.
15. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
16. Gambarin-Gelwan M., Wolf D.C., Shapiro R., et al. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000, 95:1535-1538.
17. Teefey S.A., Hildeboldt C.C., Dehdashti F., et al. Detection of primary hepatic malignancy in liver transplant candidates: Prospective comparison of CT, MR imaging, US, and PET. Radiology 2003, 226:533-542.
18. Soloway RD, Gale MB. Ultrasound plus AFP can replace CT/MRI screening for liver cancer. Data presented at the 'Digestive Disease Week' meeting in New Orleans, 2010.
19. Friedrich-Rust M., Wunder K., Kriener S., et al. Liver fibrosis in viral hepatitis: Noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009, 252:595-604.
20. Andersen E.S., Christensen P.B., Weis N. Transient elastography for liver fibrosis diagnosis. Eur J Intern Med 2009, 20:339-342.
21. Wilson S.R., Withers C.E. The Liver. Diagnostic Ultrasound 2005, 77-146. CV Mosby, Co, St Louis, MO. 3rd edn. C.M. Rumack, S.R. Wilson, J.W. Charboneau (Eds.).
22. Gheorghe L., Iacob S., Iacob R., et al. Real time elastography-A non-invasive diagnostic method of small hepatocellular carcinoma in cirrhosis. J Gastrointest Liver Dis 2009, 18:439-446.
23. Lencioni R., Piscaglia F., Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008, 48:848-857.
24. Lencioni R., Cioni D., Bartolozzi C. Tissue harmonic and contrast-specific imaging: Back to gray scale in ultrasound. Eur Radiol 2002, 12:151-165.
25. Blomley M., Albrecht T., Cosgrove D., et al. Stimulated acoustic emission in liver parenchyma with levovist. Lancet 1998, 351:568.
26. Marelli C. Preliminary experience with NC100100, a new ultrasound contrast agent for intravenous injection. Eur Radiol 1999, 9(suppl 3):S343-S346.
27. Morel D.R., Schwieger I., Hohn L., et al. Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol 2000, 35:80-85.
28. Maruyama H., Matsutani S., Saisho H., et al. Different behaviors of microbubbles in the liver: Time-related quantitative analysis of two ultrasound contrast agents, levovist and Definity. Ultrasound Med Biol 2004, 30:1035-1040.
29. von Herbay A., Vogt C., Häussinger D. Late-phase pulse-inversion sonography using the contrast agent levovist: Differentiation between benign and malignant focal lesions of the liver. AJR 2002, 179:1273-1279.
30. Bryant T.H., Blomley M.J., Albrecht T., et al. Improved characterization of liver lesions with liver-phase uptake of liver-specific microbubbles: Prospective multicenter study. Radiology 2004, 232:799-809.
31. Dietrich C.F., Ignee A., Trojan J., et al. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 2004, 53:401-405.
32. Von Herbay A., Vogt C., Willers R., et al. Real-time imaging with the sonographic contrast agent SonoVue: Differentiation between benign and malignant hepatic lesions. J Ultrasound Med 2004, 23:1557-1568.
33. Nicolau C., Vilana R., Catalá V., et al. Importance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions. AJR 2006, 186:158-167.
34. Ebara M., Ohto M., Sugiura N., et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 1990, 5:616-626.
35. Livraghi T., Bolondi L., Lazzaroni S., et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 1992, 69:925-929.
36. Redvanly R.D., Chezmar J.L., Strauss R.M., et al. Malignant hepatic tumors: Safety of high-dose percutaneous ethanol ablation therapy. Radiology 1993, 188:283-285.
37. Goldberg S.N., Gazelle G.S., Solbiati L., et al. Radiofrequency tissue ablation: Increased lesion diameter with a perfusion electrode. Acad Radiol 1996, 3:636-644.
38. Solbiati L., Goldberg S.N., Ierace T., et al. Hepatic metastases: Percutaneous radio-frequency ablation with cooled-tip electrodes. Radiology 1997, 205:367-373.
39. Ryu M., Shimamura Y., Kinoshita T., et al. Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: A retrospective multicenter study. Jpn J Clin Oncol 1997, 27:251-257.
40. Schweiger G.D., Brown B.P., Pelsang R.E., et al. CT fluoroscopy: Technique and utility in guiding biopsies of transiently enhancing hepatic masses. Abdom Imaging 2000, 25:81-85.
41. Shibata T., Iimuro Y., Yamamoto Y., et al. CT-guided transthoracic percutaneous ethanol injection for hepatocellular carcinoma not detectable with US. Radiology 2002, 223:115-120.
42. Kickuth R., Laufer U., Hartung G., et al. 3D CT versus axial helical CT versus conventional tomography in the classification of acetabular fractures: A ROC analysis. Clin Radiol 2002, 57:140-145.
43. Solomon S.B., Bohlman M.E., Choti M.A. Percutaneous gadolinium injection under MR guidance to mark target for CT-guided radiofrequency ablation. J Vasc Interv Radiol 2002, 13:419-421.
44. Cioni D., Lencioni R., Bartolozzi C. Therapeutic effect of transcatheter arterial chemoembolization on hepatocellular carcinoma: Evaluation with contrast-enhanced harmonic power Doppler ultrasound. Eur Radiol 2000, 10:1570-1575.
45. Morimoto M., Shirato K., Sugimori K., et al. Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR 2003, 181:65-69.
46. Pompili M., Riccardi L., Covino M., et al. Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver Int 2005, 25:954-961.
47. Kennedy J.E., Wu F., ter Haar G.R., et al. High-intensity focused ultrasound for the treatment of liver tumours. Ultrasonics 2004, 42:931-935.
48. Li C.X., Xu G.L., Jiang Z.Y., et al. Analysis of clinical effect of high-intensity focused ultrasound on liver cancer. World J Gastroenterol 2004, 10:2201-2204.
49. Wu F., Wang Z.B., Chen W.Z., et al. Advanced hepatocellular carcinoma: Treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology 2005, 235:659-667.